Catálogo de publicaciones - revistas
Cancer Cytopathology
Resumen/Descripción – provisto por la editorial
No disponible.
Palabras clave – provistas por la editorial
No disponibles.
Disponibilidad
| Institución detectada | Período | Navegá | Descargá | Solicitá |
|---|---|---|---|---|
| No detectada | desde ene. 1997 / hasta dic. 2023 | Wiley Online Library |
Información
Tipo de recurso:
revistas
ISSN impreso
0008-543X
ISSN electrónico
1097-0142
País de edición
Estados Unidos
Cobertura temática
Tabla de contenidos
doi: 10.1002/cncr.34711
Top advances of the year: Neuro‐oncology
Mary M. Barden
; Antonio M. Omuro
Palabras clave: Cancer Research; Oncology.
Pp. 1467-1472
doi: 10.1002/cncr.34837
Complete prevalence of primary malignant and non‐malignant brain tumors in comparison to other cancers in the United States
Corey Neff; Mackenzie Price; Gino Cioffi; Carol Kruchko; Kristin A. Waite; Jill S. Barnholtz‐Sloan; Quinn T. Ostrom
Palabras clave: Cancer Research; Oncology.
Pp. No disponible
doi: 10.1002/cncr.34843
Unrelated or haploidentical allogeneic hematopoietic cell transplantation in second complete remission for acute myeloid leukemia—Improved outcomes over time: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party study
Rama Al Hamed; Maud Ngoya; Jacques‐Emmanuel Galimard; Henrik Sengeloev; Tobias Gedde‐Dahl; Aleksandr Kulagin; Uwe Platzbecker; Ibrahim Yakoub‐Agha; Jenny L. Byrne; Thomas Valerius; Gerard Socie; Nicolaus Kröger; Didier Blaise; Ali Bazarbachi; Jaime Sanz; Fabio Ciceri; Arnon Nagler; Mohamad Mohty
Palabras clave: Cancer Research; Oncology.
Pp. No disponible
doi: 10.1002/cncr.34942
Consensus recommendations in the management of Ewing sarcoma from the National Ewing Sarcoma Tumor Board
Ajay Gupta; Richard F. Riedel; Chirag Shah; Scott C. Borinstein; Michael S. Isakoff; Rashmi Chugh; Jeremy M. Rosenblum; Erin S. Murphy; Shauna R. Campbell; Catherine M. Albert; Stacey Zahler; Stefanie M. Thomas; Matteo Trucco
Palabras clave: Cancer Research; Oncology.
Pp. No disponible
doi: 10.1002/cncr.35004
Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors. A study from the Acute Leukemia Working Party of the Euro
Sebastian Giebel; Myriam Labopin; Urpu Salmenniemi; Gerard Socié; Sergey Bondarenko; Didier Blaise; Nicolaus Kröger; Jan Vydra; Anna Grassi; Francesca Bonifazi; Tomasz Czerw; Achilles Anagnostopoulos; Bruno Lioure; Annalisa Ruggeri; Bipin Savani; Alexandros Spyridonidis; Jaime Sanz; Zinaida Peric; Arnon Nagler; Fabio Ciceri; Mohamad Mohty
<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>The aim of this study was to compare two immunosuppressive strategies, based on the use of either rabbit antithymocyte globulin (ATG) or posttransplant cyclophosphamide (PTCY), as a prophylaxis of graft‐versus‐host disease (GVHD) for patients with acute lymphoblastic leukemia (ALL) in first complete remission who underwent hematopoietic cells transplantation from matched unrelated donors.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Overall, 117 and 779 adult patients who received PTCY and ATG, respectively, between the years 2015 and 2020 were included in this retrospective study. The median patient age was 40 and 43 years in the PTCY and ATG groups, respectively, and 37% and 35% of patients, respectively, had Philadelphia chromosome‐positive ALL.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>In univariate analysis, the cumulative incidence of acute and chronic GVHD did not differ significantly between the study groups. The cumulative incidence of relapse at 2 years was reduced in the PTCY group (18% vs. 25%; <jats:italic>p</jats:italic> = .046) without a significant impact on nonrelapse mortality (11% vs. 16% in the ATG group; <jats:italic>p</jats:italic> = .29). The rates of leukemia‐free survival (LFS) and overall survival were 71% versus 59%, respectively (<jats:italic>p</jats:italic> = .01), and 82% versus 74%, respectively (<jats:italic>p</jats:italic> = .08). In multivariate analysis, the receipt of ATG compared with PTCY was associated with a reduced risk of extensive chronic GVHD (hazard ratio, 0.54; 95% confidence interval, 0.3–0.98; <jats:italic>p</jats:italic> = .04) and an increased risk of low LFS (hazard ratio, 1.57; 95% confidence interval, 1.01–2.45; <jats:italic>p</jats:italic> = .045).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>The receipt of ATG compared with PTCY, despite the reduced risk of extensive chronic GVHD, is associated with inferior LFS in adults with ALL who undergo hematopoietic cell transplantation from 10/10 human leukocyte antigen‐matched unrelated donors. These findings warrant verification in prospective trials.</jats:p></jats:sec>
Palabras clave: Cancer Research; Oncology.
Pp. No disponible
doi: 10.1002/cncr.34896
Guidelines for surveillance of patients with von Hippel‐Lindau disease: Consensus statement of the International VHL Surveillance Guidelines Consortium and VHL Alliance
Anthony B. Daniels; Amit Tirosh; Kristin Huntoon; Gautam U. Mehta; Philippe E. Spiess; Debra L. Friedman; Steven G. Waguespack; Jill E. Kilkelly; Surya Rednam; Sumit Pruthi; Eric A. Jonasch; Laura Baum; Jad Chahoud;
<jats:p>Von Hippel‐Lindau disease is a rare inherited cancer‐predisposition syndrome. The authors report the updated recommendations for the multiorgan surveillance protocols.</jats:p>
Palabras clave: Cancer Research; Oncology.
Pp. 2927-2940